Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination
Public ClinicalTrials.gov record NCT01321463. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study To Evaluate The Efficacy And Safety Of Once-Daily Orally Administered PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) On A Background Of Salmeterol Xinafoate/ Fluticasone Propionate Combination
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PH-797804 is an oral ant-inflammatory drug that may reduce the inflammation that is associated with COPD. PH-797804 will be dosed to patients with COPD to evaluate its potential safety and efficacy profile in COPD.
Study identification
- NCT ID
- NCT01321463
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 377 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2011 (Type not available)
- Primary completion
- Jun 2012 (Actual)
- Completion
- Jun 2012 (Actual)
- Last update posted
- Jul 11, 2013
2011 – 2012
United States locations
- U.S. sites
- 22
- U.S. states
- 12
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Mobile | Alabama | 36608 | — |
| Pfizer Investigational Site | Glendale | Arizona | 85306 | — |
| Pfizer Investigational Site | San Diego | California | 92120 | — |
| Pfizer Investigational Site | Clearwater | Florida | 33756 | — |
| Pfizer Investigational Site | Pensacola | Florida | 32504 | — |
| Pfizer Investigational Site | Tampa | Florida | 33603 | — |
| Pfizer Investigational Site | Tampa | Florida | 33613 | — |
| Pfizer Investigational Site | Trinity | Florida | 34655 | — |
| Pfizer Investigational Site | Conyers | Georgia | 30094 | — |
| Pfizer Investigational Site | Duluth | Georgia | 30096 | — |
| Pfizer Investigational Site | Norcross | Georgia | 30071 | — |
| Pfizer Investigational Site | Livonia | Michigan | 48152 | — |
| Pfizer Investigational Site | Fridley | Minnesota | 55432 | — |
| Pfizer Investigational Site | Minneapolis | Minnesota | 55407 | — |
| Pfizer Investigational Site | Rochester | Minnesota | 55905 | — |
| Pfizer Investigational Site | St Louis | Missouri | 63141 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45231 | — |
| Pfizer Investigational Site | Cincinnati | Ohio | 45245 | — |
| Pfizer Investigational Site | Lincoln | Rhode Island | 02865 | — |
| Pfizer Investigational Site | Spartanburg | South Carolina | 29303 | — |
| Pfizer Investigational Site | Houston | Texas | 77030 | — |
| Pfizer Investigational Site | McKinney | Texas | 75069 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 52 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01321463, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 11, 2013 · Synced Nov 7, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01321463 live on ClinicalTrials.gov.